Figure 3.
Control of WBC counts during follow-up by randomized dose (data unavailable for MRC CML IV patients). The aim was to keep the WBC count between 2 and 4 × 109/L, using additional hydroxyurea if necessary. Solid line indicates high-dose IFN-alfa (5 MIU/m2 daily); dotted line, low-dose IFN-alfa (3 MIU 5 times a week).
